A
Atox Bio
Innovative immunomodulators targeting life-threatening infections and critical conditions
About Atox Bio
Atox Bio is a late-stage biotechnology company specializing in the development of novel immunomodulators for critically ill patients. The company's lead product, Reltecimod, is designed to treat Necrotizing Soft Tissue Infections (NSTI), a rare and life-threatening condition. Atox Bio recently completed a Phase 3 clinical trial for Reltecimod in NSTI patients and is currently conducting another Phase 3 study for Acute Kidney Injury (AKI). Additional indications are in preclinical stages. The company primarily serves healthcare providers and operates within the biopharmaceutical market. Atox Bio's business model revolves around the research, development, and commercialization of its proprietary treatments. Revenue is generated through the successful development and eventual sale or licensing of its therapeutic products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2003
- Headquarters
- Ness Ziyyona, Israel
- Open positions
- None listed
- Dealroom signal
- 23.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Bacteria, Critical medical care, Inflammatory Diseases, Immune System, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES FOther financing | Dec 2017 | $30M | $120M | Adams Street Partners · Lundbeckfonden Ventures · SR One · OrbiMed | ↗ |
| SERIES EOther financing | Jul 2014 | $23M | $92M | Lundbeckfonden Ventures · OrbiMed · SR One | — |
Growth signals
Latest recorded traffic for Atox Bio is 1K monthly website visits, down 33.3% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Esperante Ventures
Series B and later6 investors entered at this stage
SR One
Lundbeckfonden Ventures
OrbiMed
Arix Bioscience
Adams Street Partners
Integra Holdings
Other known investors1 additional known investor
The Hebrew University of Jerusalem
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Atox Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Atox Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.